WATCH: Hwang Honored as Distinguished Faculty
Published
The above video was produced by Jim Rogalski, Duke University School of Medicine
On November 9, E. Shelley Hwang, MD, MPH, was honored by the Duke Medical Alumni Association with a 2023 Distinguished Faculty Award.
Hwang, an accomplished breast surgical oncologist and research scientist, is director of the Breast Cancer Disease Group at Duke Cancer Institute, vice chair of Research in the Department of Surgery, The Mary and Deryl Hart Distinguished Professor of Surgery, and a professor in the Department of Radiology.
Hwang joined Duke a decade ago after an impressive career at the University of California, San Francisco.
In 2016, Time magazine named her one of the 100 most influential people for her work in re-framing the problem of pre-invasive breast cancer. Her work continues on this front and she remains a national leader in this area of breast cancer research and treatment.
Written By
Julie Poucher Harbin
Senior Writer, Duke Cancer Institute
Topics
Related News
Targeted Therapies Show Dramatic Improvements in Breast Cancer Patients with Rare Subtypes
Targeted therapies improve overall outcomes of patients with rare breast cancer subtypes and, in some cases, improve pathologic complete response rates (pCR) and overall survival to rates comparable to those of patients with breast cancer of no special type.Alexandra Thomas, MD, medical oncologist with the Duke Cancer Institute (DCI) breast oncology program, presented these results from the I-SPY2 trial at ASCO Breakthrough: A Global Summit for Oncology Innovators.Thomas and her team were able to retrospectively determine the tumor molecular signature and receptor status to classify the response predictive subtype (RPS).
New Research Supports Use of Targeted Therapies in Malignant Phyllodes Tumors in Breast Cancer Patients
New research suggests that targeted therapies can be used to manage malignant phyllodes tumors (MPTs), a rare tumor of the breast with aggressive biologic behavior and high recurrence rates.Duke Cancer Institute breast oncology program members Rani Bansal, MD, and Laura Rosenberger, MD, MS, worked together on this research published in JCO Precision Oncology. Bansal is a medical oncologist, and Rosenberger is a surgical oncologist.MPTs are a type of growth that involves fibrous tissue and surface epithelium. Surgery is the primary treatment option for these tumors; however, Bansal and Rosenberger’s research assessed the molecular structure to reveal new possible treatment opportunities.Study participants underwent genomic sequencing, whole-transcriptome sequencing, and immunochemistry to identify pathogenic fusions to determine potential targeted treatment options. Bansal said this revealed that participants showed prolonged benefit from targeted therapy, with some being able to stay on one targeted therapy for longer than one year.While there are currently many drugs with approval from the Food and Drug Administration (FDA) across various tumor types, such as trastuzumab deruxtecan (T-DXd) for HER2-positive or HER2-low tumors, Bansal believes more options will be available soon.“As the treatment landscape for oncology continues to expand, we will see more targeted therapies available for patients, and we can personalize their systemic treatment to their specific cancer,” she said.While surgical resection remains the mainstay for treating MPTs, this research shows further investigation into how to incorporate targeted therapies into treatment plans is warranted. Bansal and Rosenberger are currently looking into clinical trials to continue this examination.“These results will certainly guide clinical trial design and options for those with specific mutations,” Rosenberger said.This research marks an important first step in understanding next-generation sequencing in MPTs and, hopefully, developing more targeted and effective treatment options for patients.“As we continue to collect data on phyllodes tumors I think continuing to investigate this rare tumor group with more samples and correlating with clinical outcomes could lead to potential therapeutic advances,” Bansal said. “This is just the beginning, and our data shows clinical utility for sending next-generation sequencing for these tumors.”
Related News
Targeted Therapies Show Dramatic Improvements in Breast Cancer Patients with Rare Subtypes
Targeted therapies improve overall outcomes of patients with rare breast cancer subtypes and, in some cases, improve pathologic complete response rates (pCR) and overall survival to rates comparable to those of patients with breast cancer of no special type.Alexandra Thomas, MD, medical oncologist with the Duke Cancer Institute (DCI) breast oncology program, presented these results from the I-SPY2 trial at ASCO Breakthrough: A Global Summit for Oncology Innovators.Thomas and her team were able to retrospectively determine the tumor molecular signature and receptor status to classify the response predictive subtype (RPS).
New Research Supports Use of Targeted Therapies in Malignant Phyllodes Tumors in Breast Cancer Patients
New research suggests that targeted therapies can be used to manage malignant phyllodes tumors (MPTs), a rare tumor of the breast with aggressive biologic behavior and high recurrence rates.Duke Cancer Institute breast oncology program members Rani Bansal, MD, and Laura Rosenberger, MD, MS, worked together on this research published in JCO Precision Oncology. Bansal is a medical oncologist, and Rosenberger is a surgical oncologist.MPTs are a type of growth that involves fibrous tissue and surface epithelium. Surgery is the primary treatment option for these tumors; however, Bansal and Rosenberger’s research assessed the molecular structure to reveal new possible treatment opportunities.Study participants underwent genomic sequencing, whole-transcriptome sequencing, and immunochemistry to identify pathogenic fusions to determine potential targeted treatment options. Bansal said this revealed that participants showed prolonged benefit from targeted therapy, with some being able to stay on one targeted therapy for longer than one year.While there are currently many drugs with approval from the Food and Drug Administration (FDA) across various tumor types, such as trastuzumab deruxtecan (T-DXd) for HER2-positive or HER2-low tumors, Bansal believes more options will be available soon.“As the treatment landscape for oncology continues to expand, we will see more targeted therapies available for patients, and we can personalize their systemic treatment to their specific cancer,” she said.While surgical resection remains the mainstay for treating MPTs, this research shows further investigation into how to incorporate targeted therapies into treatment plans is warranted. Bansal and Rosenberger are currently looking into clinical trials to continue this examination.“These results will certainly guide clinical trial design and options for those with specific mutations,” Rosenberger said.This research marks an important first step in understanding next-generation sequencing in MPTs and, hopefully, developing more targeted and effective treatment options for patients.“As we continue to collect data on phyllodes tumors I think continuing to investigate this rare tumor group with more samples and correlating with clinical outcomes could lead to potential therapeutic advances,” Bansal said. “This is just the beginning, and our data shows clinical utility for sending next-generation sequencing for these tumors.”